Summary
- Profile Type
- Technology offer
- POD Reference
- TOHU20230517016
- Term of Validity
- 17 May 2023 - 16 May 2025
- Company's Country
- Hungary
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- Pre-clinical Hungarian CRO offers dry powder inhalation exposure technology for pre-clinical pharmacokinetics (PK) and pharmacodynamics (PD) studies. The service allows the requestor to assess the efficacy of his active pharmaceutical ingredient (API) on a pulmonary animal model following acute or repeated nose-only dry powder inhalation administration. The company is looking for partners for research cooperation or commercial agreement with technical assistance.
- Full Description
-
The SME operates as pre-clinical CRO in Hungary. It offers support for research groups or pharmaceutical companies that are active or interested in the development of inhalation drug formulations, especially as dry powder ones.
The company is specialized in carrying out animal models on immune-inflammation including inflammatory pulmonary disorders like asthma, COPD (chronic obstructive pulmonary disease) or fibrosis. The company has laboratory rodent inhalation system for controlled dose inhalation exposure.
The staff has been active on respiratory pharmacology for several decades and gained expertise in a multinational R&D organisation. The company has broad range of scientific equipment to evaluate readouts from the experimental samples.
Research groups usually find difficult organisations (e.g. preclinical CROs) where the fine dosed dry powder inhalation technology and pre-clinical animal models on pulmonary disease indications are up and running together. The Hungarian SME offers solution and support to these groups.
The company is looking for SMEs and research groups to work together in the frame of research/technical cooperation. - Advantages and Innovations
-
• The approach may be of interest of research groups developing powder inhalation formulations for the treatment of pulmonary indications.
• Dry powder nose-only treatment/exposure and pharmacology models on the same site.
• Experience in dry powder inhalation drug administration technology is alloyed with high level expertise on pre-clinical pulmonary animal models.
• The technology is suitable to do both pharmacokinetics and pharmacodynamics studies with API and/or API drug formulations. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- Secret know-how
Partner Sought
- Expected Role of a Partner
-
- Type of partner sought: Research institute, SME.
- Specific area of activity of the partner: Drug R&D, air pollution toxicology.
- Task to be performed: Drug pre-formulation before sending it to inhalation exposure. - Type and Size of Partner
- SME <=10
- SME 50 - 249
- R&D Institution
- University
- SME 11-49
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 03004007 - Pharmaceutics
- 06001015 - Pharmaceutical Products / Drugs
- Market keywords
- 05003005 - Drug delivery and other equipment
- 05007002 - Pharmaceuticals/fine chemicals
- 05005007 - Pulmonary medicine
- Sector Groups Involved
- Health
- Targeted countries
- All countries